



METHOD ARTICLE

REVISÉD Liquid chromatography–tandem mass spectrometry for the simultaneous quantitation of ceftriaxone, metronidazole and hydroxymetronidazole in plasma from seriously ill, severely malnourished children [version 2; referees: 3 approved, 1 approved with reservations]

Martin Ongas ^{1,2}, Joseph Standing ^{3,4}, Bernhards Ogutu ^{1,2}, Joseph Waichungo ⁵, James A. Berkley ⁵⁻⁷, Karin Kipper ^{4,8,9}

¹Center for Research in Therapeutic Sciences, Strathmore University, Ole Sangale Road, Nairobi, Kenya

²KEMRI-Centre for Clinical Research, Nairobi, Kenya

³Inflammation, Infection and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, 30 Guilford Street, London, WC1N 1EH, UK

⁴Paediatric Infectious Diseases Research Group, Institute for Infection and Immunity, St. George's, University of London, Cranmer Terrace, London, SW17 0RE, UK

⁵KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

⁶Centre for Tropical Medicine & Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, UK

⁷The Childhood Acute Illness & Nutrition (CHAIN) Network, Lenana Place, Nairobi, Kenya

⁸Analytical Services International, St George's University of London, Cranmer Terrace, London, SW17 0RE, UK

⁹Institute of Chemistry, University of Tartu, Tartu, Estonia

v2 First published: 19 Jun 2017, 2:43 (doi: [10.12688/wellcomeopenres.11728.1](https://doi.org/10.12688/wellcomeopenres.11728.1))
Latest published: 30 Jan 2018, 2:43 (doi: [10.12688/wellcomeopenres.11728.2](https://doi.org/10.12688/wellcomeopenres.11728.2))

Abstract

We have developed and validated a novel, sensitive, selective and reproducible reversed-phase high-performance liquid chromatography method coupled with electrospray ionization mass spectrometry (HPLC–ESI–MS/MS) for the simultaneous quantitation of ceftriaxone (CEF), metronidazole (MET) and hydroxymetronidazole (MET-OH) from only 50 µL of human plasma, and unbound CEF from 25 µL plasma ultra-filtrate to evaluate the effect of protein binding. Cefuroxime axetil (CEFU) was used as an internal standard (IS). The analytes were extracted by a protein precipitation procedure with acetonitrile and separated on a reversed-phase Polaris 5 C18-Analytical column using a mobile phase composed of acetonitrile containing 0.1% (v/v) formic acid and 10 mM aqueous ammonium formate pH 2.5, delivered at a flow-rate of 300 µL/min. Multiple reaction monitoring was performed in the positive ion mode using the transitions m/z 555.1→ m/z 396.0 (CEF), m/z 172.2→ m/z 128.2 (MET), m/z 188.0→ m/z 125.9 (MET-OH) and m/z 528.1→ m/z 364.0 (CEFU) to quantify the drugs. Calibration curves in spiked plasma and ultra-filtrate were linear ($r^2 \geq 0.9948$) from 0.4–300 µg/mL for CEF, 0.05–50 µg/mL for MET and 0.02 – 30 µg/mL for MET-OH. The intra- and inter- assay precisions were less than 9% and the mean extraction recoveries were 94.0% (CEF), 98.2% (MET), 99.6% (MET-OH) and 104.6% (CEF in ultra-filtrate); the recoveries for the IS were 93.8% (in plasma) and 97.6% (in ultra-filtrate). The validated method was

Open Peer Review

Referee Status:

| | Invited Referees | | | |
|--|------------------|--------|--------|--------|
| | 1 | 2 | 3 | 4 |
| version 2 published 30 Jan 2018 | | | | |
| | | report | report | report |
| version 1 published 19 Jun 2017 | | | | |
| | report | report | report | report |

- Laurens Manning**, Fiona Stanley Hospital, Australia
- I-Lin Tsai**, Taipei Medical University, Taiwan
- Sandrine Lefevre**, CHR Orléans, France

successfully applied to a pharmacokinetic study of CEF, MET and MET-OH in hospitalized children with complicated severe acute malnutrition following an oral administration of MET and intravenous administration of CEF over the course of 72 hours.

4 **Pascal Houzé**, Paris Descartes University, France

Discuss this article

Comments (0)

KEMRI|Wellcome Trust

This article is included in the [KEMRI | Wellcome Trust](#) gateway.

Corresponding author: Karin Kipper (kkipper@sgul.ac.uk)

Author roles: **Ongas M:** Supervision, Writing – Review & Editing; **Standing J:** Validation, Writing – Original Draft Preparation; **Ogutu B:** Supervision, Writing – Original Draft Preparation; **Waichungo J:** Resources, Supervision; **Berkley JA:** Project Administration; **Kipper K:** Resources, Supervision, Writing – Review & Editing

Competing interests: No competing interests were disclosed. No writing assistance was utilized in the production of this manuscript.

How to cite this article: Ongas M, Standing J, Ogutu B *et al.* **Liquid chromatography–tandem mass spectrometry for the simultaneous quantitation of ceftriaxone, metronidazole and hydroxymetronidazole in plasma from seriously ill, severely malnourished children [version 2; referees: 3 approved, 1 approved with reservations]** Wellcome Open Research 2018, 2:43 (doi: [10.12688/wellcomeopenres.11728.2](https://doi.org/10.12688/wellcomeopenres.11728.2))

Copyright: © 2018 Ongas M *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution Licence](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Grant information: JS has received funding from United Kingdom Medical Research Council Fellowships (grants G1002305 and M008665), and been supported by the National Institute for Health. KK has received funding from the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under REA grant agreement no. 608765 and from the Estonian Research Council grant agreement PUTJD 22. JB received funding for this work within the First-Line Antimicrobials in Children with Complicated Severe Acute Malnutrition (FLACSAM) trial from the MRC/DfID/Wellcome Trust Joint Global Health Trials Scheme (MR/M007367/1), and is funded by the Bill & Melinda Gates Foundation for the Childhood Acute Illness & Nutrition (CHAIN) Network (OPP1131320).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

First published: 19 Jun 2017, 2:43 (doi: [10.12688/wellcomeopenres.11728.1](https://doi.org/10.12688/wellcomeopenres.11728.1))

REVISED Amendments from Version 1

Valuable input from all the reviewers has been taken into account in the improved second version of the manuscript. Major clarifications have been added to figure captions, with [Figure 2](#) and [Figure 4](#) being revised. Several sections of the manuscript have been changed to improve the clarity and readability, and the [supplementary material](#) has all been updated.

See referee reports

Introduction

Serious infections are common in children, especially those with severe acute malnutrition (SAM) admitted sick to hospitals, with over 50% of patients estimated to be infected at any one time^{1,2}. Mortality remains high in this patient group, despite implementation of current treatment guidelines³. Although empiric antibiotics are routinely given⁴⁻⁷, it is not clear whether the currently recommended regimen is the most effective in the context of increasing antimicrobial resistance (AMR), and moreover whether expected therapeutic levels are achieved in this group of patients.

To resolve this question, a large clinical trial of metronidazole (MET) and ceftriaxone (CEF) versus standard care (penicillin or ampicillin plus gentamicin) is planned. However, first, a study of the pharmacokinetics (PK) of MET and CEF is needed in order to optimize the dosing strategy in severely malnourished children,

since they may have altered absorption, body composition, volume of distribution, available plasma proteins for binding, or metabolism and elimination through hepatic and renal pathways^{8,9}. A quantitative determination of MET and CEF in plasma is essential in order to evaluate the pharmacokinetics of these co-administrated antibiotics ([Figure 1](#)).

Previous studies have indicated the activity of MET and its two principle metabolites, 1-(2-hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole (the “alcohol” metabolite, MET-OH) and 2-methyl-5-nitroimidazole-1-acetic acid (the “acid” metabolite) against a broad range of anaerobic bacteria^{10,11}. In this study however, we focus on the major active metabolite (the “alcohol” metabolite). Several methods have been reported for quantification of either MET¹²⁻¹⁵ or MET and its metabolites^{11,16} in human plasma or serum. O’Keefe *et al.*¹¹ evaluated the activity of the metronidazole metabolites against anaerobic bacteria; however, the LC-UV method was limited in quantifying lower levels of the metabolites in a biological matrix due to its low sensitivity and poor selectivity. Silva *et al.*¹² developed an HPLC-MS-MS method for the quantitation of metronidazole in plasma. The method required large sample volumes and complex sample preparation steps, with large volumes of extraction solvents.

CEF, like other β -lactam antibiotics, is highly protein bound. Wong *et al.*¹⁷ reported average protein binding of 89.5%. It has also been noted that ceftriaxone protein binding is nonlinear, becoming saturated at higher concentrations and linked with serum albumin concentrations in critically ill patients¹⁸.




Figure 1. Chemical structures of ceftriaxone (A), metronidazole (B), hydroxymetronidazole (D) and cefuroxime axetil, IS (C).

Given the significant effects of protein binding on clinical exposure to highly bound drugs^{17,19–23}, and given that the free drug is important for antimicrobial effect, it was necessary to develop a method to measure the unbound ceftriaxone appropriate for use in seriously ill malnourished children. Some of the methods reported previously^{24,25} give approaches to measurement of unbound fractions of compounds using equilibrium dialysis, which are more prone to environmental interference and much more laborious in sample preparations. Other methods involved the use of HPLC with UV detection, but did not consider the protein binding of CEF^{26–29}.

We aimed to develop the first simultaneous HPLC-ESI-MS/MS method for rapid, simple, reliable, sensitive and selective quantitation of MET, CEF and MET-OH in a small volume (50 μ L) of human plasma, and unbound CEF from (25 μ L) plasma ultra-filtrate.

Materials and methods

Chemicals

Ceftriaxone sodium (CEF; batch no. 3.2, purity 90.4%; MW=554.58 g/mol), metronidazole (MET; batch no. 2.1, purity 100%, MW=171.15 g/mol) and cefuroxime axetil (CEFU, batch no. 4.0, purity 97.3%, MW=510.47 g/mol) were purchased from European Directorate for the Quality of Medicines and Healthcare (Strasbourg, France). Hydroxymetronidazole (MET-OH; Lot no. 4276, purity 98.2%, MW=187.15 g/mol) was purchased from LGC (Teddington, UK). Acetonitrile and methanol (both LC-MS grade), formic acid (85%; AnalaR[®] grade) and ammonium formate (AnalaR[®] grade) were purchased from Sigma Aldrich (St. Louis, MO, USA). Deionized water was prepared using a Smart2 Pure[™] water purification system (Thermo-scientific, Niederelbert, Germany). Blank human plasma with Li-heparin for the preparation of calibrators and quality controls was obtained from Kenya Medical Research Institute, Centre for Clinical Research (Nairobi, Kenya). The matrix used to quantify free fraction of ceftriaxone was plasma ultrafiltrate obtained by ultrafiltration of drug-free plasma.

Sample preparation

Total drug. To a 50 μ L aliquot of plasma (blank, standard, quality control, or patient sample) 200 μ L of internal standard (CEFU; of a 1.25 μ g/mL solution in acetonitrile) was added. The 1.5 mL polypropylene tubes were vortex-mixed for 3 minutes to precipitate the plasma proteins, followed by centrifugation (4000 x g; 10 min, 4°C). The supernatant (100 μ L) was transferred into another clean 1.5 mL polypropylene tube and diluted with 400 μ L of 20% methanol in water. The samples were vortex-mixed for 3 minutes and submitted for analysis by LC-MS/MS.

Unbound ceftriaxone. About a 300 μ L aliquot of patient plasma was taken into a clean 1.5 mL polypropylene tube and incubated on a Grant JB Series incubation bath (Grant Instruments, Cambridge, UK) at 37°C for 1 h, then transferred into Centrifree[®] Ultrafiltration Device (Merck Millipore Ltd, Darmstadt, Germany) and centrifuged on a Thermo Fisher Scientific SL 40R centrifuge (2000 x g; 30min, 37°C). 25 μ L sample ultra-filtrate was taken

into another clean 1.5 mL polypropylene tube; internal standard solution (200 μ L, 1.0 μ g/mL) in acetonitrile was added to the sample and diluted to 1 mL with 20% methanol in water. The samples were vortex-mixed for 3 min and submitted for analysis by LC-MS/MS. Calibrators and quality control (QC) samples were prepared by ultrafiltration of blank plasma after 1h incubation at 37°C, 200 μ L aliquots the ultrafiltrate were spiked with 50 μ L of CEF working solutions to produce 0.4, 12, 24, 48, 96, 150, 220, 300 μ g/mL CEF and 1.2, 120, 240 μ g/mL QCs.

Preparation of analytical standards

Stock solutions of CEF (5 mg of the base/mL), MET and MET-OH (both 1 mg/mL) were prepared by dissolving an appropriate amount of each compound in 20% methanol. The stock solutions were further serially diluted with 20% methanol to make working standard solutions used to spike the blank plasma to produce 0.4, 12, 24, 48, 96, 150, 220, 300 μ g/mL CEF and 1.2, 120, 240 μ g/mL QCs; 0.05, 1.0, 2.0, 4.0, 8.0, 16.0, 32.0, 50 μ g/mL MET and 0.15, 20, 40 μ g/mL QCs; 0.02, 0.8, 1.6, 3.2, 6.4, 13, 20, 30 μ g/mL MET-OH and 0.06, 12, 24 μ g/mL QCs. Stock solution of CEFU (IS) was prepared by dissolving appropriate amount of the compound in acetonitrile, the stock solution was serially diluted with acetonitrile to make working standard solutions of 1.25 μ g/mL and 1 μ g/mL. All the stock solutions were stored at -20°C, protected from light (in amber sample vials) and used within three months.

Chromatographic conditions

The equipment consisted of an Agilent Technologies HPLC-ESI-MS/MS system (Santa Clara, CA, USA), composed of a 1260 μ Quaternary Pumps, 1260 Autosampler and 1260 Thermosetting Column Compartment (TCC). Chromatographic separation was performed on a Polaris 5 C18-A (150 mm x 3.0 mm I.D; 3.0 μ m particle size) analytical column from Agilent Technologies (Santa Clara, CA, USA) with a C18 guard cartridge (4 mm x 3.0 mm, 3.0 μ m) (Phenomenex, Torrance, CA, USA) maintained at 30°C. The mobile phase consisted of (A) 10mM aqueous ammonium formate pH 2.5 and (B) 0.1% formic acid in acetonitrile. A linear gradient elution was used to deliver the mobile phase, 40% solvent B at time 0 min, and 100% from 1.8 min, to 5.5 min, and back to 40% from 6 min to 12 min, (re-equilibration step). The flow rate was set at 300 μ L/min, an injection volume of 5 μ L was used to optimize the drug signals and for analysis.

Mass spectrometry

Mass spectrometric detection of analytes was performed on a 6410 Triple Quadrupole Mass Spectrometer with an Electrospray Ionization (ESI) source from Agilent Technologies (Santa Clara, CA, USA) in positive ionization mode. Nitrogen was used as the nebulizing, desolvation and collision gas, the optimized ion source parameters were: ion spray voltage 4.0 kV, exit potential 7V, RF lens 0.5 V.

Source temperature was 100°C and desolvation temperature 300°C. High purity nitrogen from Genius NM32LA generator (Peak Scientific, Scotland, UK) was used as both sheath and auxiliary gas set at 20 l/min and 12 l/min, respectively.

Multiple reaction monitoring (MRM) was employed for the data acquisition, the analytical parameters optimized for the compounds were declustering potentials (DP) and collision energies (CE) (Table 1), and the scan dwell time was set at 500 ms. for each channel. Data acquisition and analysis were accomplished with Mass Hunter software (version A.02.00; Agilent Technologies).

Validation

Method validation was performed as per the US Food and Drug Administration Guidance for Industry Bioanalytical Method Validation³⁰. The method was validated for selectivity and sensitivity, inter-day and intra-day accuracy and precision, extraction recovery, matrix effect and stability. Method's linear range was evaluated and lower limit of quantification was set to fit for purpose for the actual clinical trial samples. Carry-over was assessed in accordance with the European Medicines Agency guideline³¹.

Selectivity of the method was assessed and assured by analysis of six blank plasma samples from different sources, each blank sample was tested for interference using the proposed extraction procedure and chromatographic/mass spectrometric conditions and compared with those obtained with an aqueous solution of the analyte at a concentration near to the lower limit of quantification (LLOQ). A plasma sample fortified with cefadroxil and cefaclor was also processed and analyzed.

The standard curves were obtained through analysis of calibration standard plasma and ultra-filtrate (for free CEF) samples and plotting of peak area ratio of MET, CEF and ME-OH versus the corresponding nominal concentrations. The linearity of the standard curves were evaluated using least-squares linear regression analysis.

The analytical extraction recovery was determined by comparing the response of extracted quality control plasma samples with the response of post extracted plasma samples spiked at similar concentrations to the quality control samples.

Table 1. Compound optimization parameters for ceftriaxone (CEF), metronidazole (MET), hydroxymetronidazole (MET-OH) and cefuroxime axetil (CEFU), including multiple reaction monitoring (MRM) transitions, declustering potentials (DP) and collision energies (CE).

| Compound | Precursor ion | MRM Transition (m/z) | DP (V) | CE (eV) |
|----------|-----------------------------------|----------------------|--------|---------|
| CEF | [M+H] ⁺ | 555.1 → 396.0 | 60 | 18 |
| MET | [M+H] ⁺ | 172.2 → 128.2 | 100 | 15 |
| MET-OH | [M+H] ⁺ | 188.0 → 125.9 | 100 | 15 |
| CEFU | [M+NH ₄] ⁺ | 528.1 → 364.0 | 60 | 18 |

To evaluate the inter-assay precision and accuracy, six replicates of quality control plasma samples were analyzed together with one independent calibration standard curve, this was done in three consecutive days; while intra-assay precision and accuracy were evaluated through analysis of quality control plasma samples in replicate of six in the same day. Inter-assay and intra-assay precision were expressed as coefficient of variation (CV%).

The accuracy was expressed as the percent ratio between the experimental concentrations and the nominal concentration for each sample. A similar assessment was done for plasma ultra-filtrate to determine the accuracy and precision for the unbound ceftriaxone.

Stability (ST%) studies were evaluated via sample and solution concentrations, where:

$$ST\% = \frac{c_t}{c_0} \times 100\%. \quad (i)$$

ST% is the stability of the chemical compound in the sample over the period of time. c_0 is the initial concentration, determined without introducing any extra pauses in the analysis process. c_t is the concentration obtained after the storage period with time t .

Sub-stock solution stability was evaluated for CEF, MET and MET-OH, by comparing the response generated from the same solution at preparation and after being stored at -20°C for a period of 28 days. All the analytes were found to be stable within the period investigated and fresh stock solutions were prepared thereafter, fresh IS solution was prepared daily from weighing during the method validation and study samples analysis. The stability was reported as coefficient of variation between the initial concentration and the concentration at day 28.

Spiked plasma samples were subjected to three freeze-thaw cycles at -20°C and the analytes concentrations assessed after the third cycle. This was done also for plasma ultra-filtrate spiked with CEF to assess the stability of free ceftriaxone in calibrators and quality control samples.

Bench-top stability was evaluated by keeping plasma samples at low and high quality control levels at ambient temperatures (< 28 °C) for at least 8h then processed and analyzed. Selected ambient temperature covered the temperature range for study samples, as ambient temperatures remained < 28°C.

Processed sample stability was assessed by letting the samples stay in the autosampler at 18°C for 24h and then they were analyzed the following day. This was done to ensure data integrity in case of equipment failure and initiation of a re-run.

Long term stability of the analytes was studied over a period that covered the duration of storage of the study samples from

collection to the last sample analysis, this ensured that the integrity of study samples was not compromised over the period of storage. To investigate long term stability, two sets of sample aliquots were prepared at concentrations corresponding to low and high quality control levels. The first set was processed and analyzed at day 1 and the second set after 90 days of storage at -20°C. The analyte concentrations in the plasma and ultra-filtrate samples at 90 days of storage was compared with those obtained on day 1 to determine the percentage stability.

To assess carry-over, a processed blank sample was injected after a high concentration calibration standard at the upper limit of quantification (ULOQ) and the peak response in blank sample determined.

Two different methods were used to access and determine matrix effect. In the first method, regions of ion suppression or enhancement were evaluated by direct post column infusion of a mixture of analytes and IS at high concentration at the rate of 10 µL/min, while injecting a blank extracted plasma. In the second method, matrix effect (ion enhancement) was evaluated for MET in six different lots of plasma by comparing the response of post extracted plasma samples spiked with 0.15 µg/mL (LLOQ) and 40 µg/mL (ULOQ) of metronidazole with the response of neat standard solutions spiked at similar concentrations.

Incurred sample reanalysis was done 90 days after the initial study sample analysis. A subset of subject samples (25 samples) were selected from randomly picked study participants and analyzed against freshly spiked calibrators and QCs. The percentage variation in the two analyses were determined by:

$$\text{Variation}\% = \frac{(R_c - O_c)}{M_c} \times 100 \quad (\text{ii})$$

Where: Variation% is the percentage difference between the initial analysis and the reanalysis concentrations, R_c is the repeat analysis concentration measured, O_c is the initial analysis concentration measured, M_c is the mean of the initial and repeat analysis concentrations.

Results and discussion

Method development and chromatographic separation of the analytes

Ceftriaxone is an acidic compound possessing a β -lactam ring in its structure (Figure 1A). Like many β -lactam antibiotics, CEF is more susceptible to chemical and biological degradation due to its labile β -lactam ring^{32,33}. Metronidazole on the other hand is slightly basic and fairly resistant to degradation^{34,35}. This work is unique and novel, designed to develop a method that would be useful in simultaneous assay of CEF, MET and MET-OH from only 50 µL of human plasma, and unbound CEF from 25 µL plasma ultra-filtrate based on the physicochemical properties of these compounds and the area of method application. Moreover, the concerns raised by Berezhkovskiy *et al.*²² on temperature dependency of protein binding and the need to maintain the physiological temperature (37°C)

through the sample processing time were considered in sample pretreatment.

The method took into account the therapeutic and overdose concentration ranges. The method has been validated and proved to be reliable for the determination of the drugs in human plasma. During the method development, several chromatographic conditions were optimized for all analytes such as the mobile phase composition, pH and various flow rates. Various ratios (80:20, 70:30, 60:40 v/v) of acetonitrile and 10 mM ammonium formate were tested as starting eluent for chromatographic separation. The variation in the mobile phase led to considerable changes in the chromatographic parameters, like peak symmetry and retention time. The pH effect showed that optimized conditions are reached when the pH value of the buffer is adjusted to 2.5 with formic acid, producing well resolved and sharp peaks for all analytes assayed. Henceforth, in the present method the pH adjusted to 2.5 and the chosen LC gradient ensured sharp chromatographic peaks with the best possible baseline-resolved separations of CEF, MET, MET-OH and CEFU (IS) within 4 minutes with a total runtime of 12 minutes. With the optimized MRM transitions, the stable and most intense product ions of CEF (m/z 396.0), MET (m/z 128.2), MET-OH (m/z 125.9) and CEFU (m/z 364.0) were detected (Figure S1).

Method validation

Selectivity. All the lots of blank plasma used for selectivity studies met the acceptance criteria, no significant interferences at the retention times of the analytes or internal standard were found. Figure 2 shows the typical chromatograms of extracted blank plasma, blank plasma spiked with IS (Zero sample), a spiked plasma sample with the analytes at LLOQ and ULOQ level. It can be seen that there were no interfering peaks from endogenous compounds observed at the retention times of the analytes and the IS. Moreover, no interference was observed from plasma samples fortified with commonly used β -lactam antibiotics (cefadroxil and cefaclor), processed and analyzed as described under the proposed sample preparation procedure.

Calibration curves and limit of quantification. Calibration curves were constructed by plotting peak area ratios of analytes and IS against the nominal concentrations of CEF, MET and MET-OH. The curves for drugs spiked in plasma were found to be linear over the concentration ranges of 0.4–300 µg/mL (CEF), 0.05–50 µg/mL (MET) and 0.02–30 µg/mL (MET-OH). A weighted ($1/x^2$) linear regression model was used due to the wide range of concentrations covered by the calibration graphs. The choice of this regression model was based on all available data from the validation phase, in light of this the method proved to be reliable in terms of accuracy and reproducibility over the entire calibration range (Table S1). The coefficients of variation of the slopes of six calibration curves were 9.8% (MET), 9.4% (CEF), 6.7% (MET-OH) and 7.2% (CEF in ultra-filtrate). The LLOQs for the method were set by the needs of the clinical trial. The LLOQ is the lowest standards on the calibration curve that the method is able to identify and whilst still providing discrete and reproducible results with a precision $\leq 20\%$ and accuracy within 80%–120% (Table 2). The limits of detection (LODs) were determined as the lowest

A




Figure 2A. Representative chromatograms from extracted zero sample (with IS only), cefuroxime (RT 3.71 min).


B

Figure 2B. Representative chromatograms of ceftriaxone (RT 2.59 min), metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 min), and cefuroxime (IS) (RT 3.71 min) from extracted spiked plasma at LLOQ.


C

Figure 2C. Representative chromatograms of ceftriaxone (RT 2.59 min), metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from extracted spiked plasma at ULOQ.

concentration of the analyte at which the signal to noise (S/N) ratio exceeded 3:1³⁰. ULOQ values were determined from anticipated peak concentrations ranges of the analytes, and ensuring that the calibration points met the accuracy and reproducibility criteria of method validation.

Extraction recovery. Protein precipitation with acetonitrile was used to extract the analytes and the IS from plasma samples, this method was found to be efficient given the small sample volume (50 μ L) used that would otherwise be impossible to use with

the liquid-liquid extraction techniques employed in previously reported publications^{12,13,15} for MET and^{26–29} for CEF. This still yielded higher recoveries with better reproducibility (Table S2).

Accuracy and precision. Accuracy of the method for the analytes in plasma were between 90.0%–105.5%, and precision, measured in CV%, was always lower than 8.5%, depicting the high precision of the method. The accuracy of the method for CEF in ultra-filtrate was between 93.6%–107.2% and a precision lower than 8.1% (Table 2).

Table 2. Intra-assay and inter-assay accuracy and precision of metronidazole (MET), ceftriaxone (CEF), and hydroxymetronidazole (MET-OH) in plasma, and CEF in ultra-filtrate (CEF^{uf}) at LLOQ, LOQ, MOQ and HOQ.

| Intra-assay (n=6) | Compound | Nominal concentration (μ g/ mL) | Mean estimated concentration (μ g/ mL) \pm SD | Precision (CV %) | Accuracy (%) |
|--------------------|-------------------|--------------------------------------|--|------------------|--------------|
| | MET | 0.05 | 0.051 \pm 2.0 | 3.9 | 101.9 |
| | | 0.15 | 0.148 \pm 7.7 | 7.8 | 98.7 |
| | | 20 | 20.44 \pm 4.0 | 3.9 | 102.2 |
| | | 40 | 37.75 \pm 5.6 | 5.9 | 94.4 |
| | CEF | 0.4 | 0.39 \pm 2.5 | 3.2 | 97.5 |
| | | 1.2 | 1.10 \pm 1.5 | 1.7 | 91.7 |
| | | 120 | 112.02 \pm 3.5 | 3.7 | 93.3 |
| | | 240 | 219.51 \pm 6.8 | 7.5 | 91.5 |
| | MET-OH | 0.02 | 0.018 \pm 1.7 | 2.6 | 90.0 |
| | | 0.06 | 0.057 \pm 4.7 | 4.9 | 95.0 |
| | | 12 | 11.43 \pm 2.5 | 2.7 | 95.2 |
| | | 24 | 24.49 \pm 8.6 | 8.4 | 102.0 |
| | CEF ^{uf} | 0.4 | 0.41 \pm 5.5 | 5.3 | 100.9 |
| | | 1.2 | 1.27 \pm 5.5 | 5.2 | 105.8 |
| | | 120 | 112.32 \pm 5.1 | 5.5 | 93.6 |
| | | 240 | 253.03 \pm 8.2 | 7.8 | 105.4 |
| Inter-assay (n=18) | MET | 0.05 | 0.051 \pm 1.4 | 2.7 | 101.1 |
| | | 0.15 | 0.155 \pm 5.6 | 5.4 | 103.3 |
| | | 20 | 20.59 \pm 3.3 | 3.2 | 103.0 |
| | | 40 | 38.79 \pm 5.6 | 5.8 | 97.0 |
| | CEF | 0.4 | 0.40 \pm 2.7 | 2.9 | 100.0 |
| | | 1.2 | 1.15 \pm 3.8 | 3.9 | 95.8 |
| | | 120 | 114.54 \pm 5.1 | 5.4 | 95.4 |
| | | 240 | 226.75 \pm 5.2 | 5.5 | 94.5 |
| | MET-OH | 0.02 | 0.019 \pm 1.2 | 2.3 | 95.0 |
| | | 0.06 | 0.059 \pm 5.2 | 5.3 | 98.3 |
| | | 12 | 12.01 \pm 4.8 | 4.8 | 100.1 |
| | | 24 | 24.51 \pm 4.7 | 4.6 | 102.1 |
| | CEF ^{uf} | 0.4 | 0.43 \pm 5.8 | 7.4 | 107.2 |
| | | 1.2 | 1.22 \pm 8.3 | 8.1 | 101.6 |
| | | 120 | 115.32 \pm 5.1 | 5.3 | 96.1 |
| | | 240 | 251.30 \pm 6.2 | 5.9 | 104.6 |

Stability (ST%)

The results of all the stability studies obtained were well within the acceptable limits of accuracy ($\pm 15\%$) and precision ($CV \leq 15\%$) (Table 3).

Sub-stock stability. All analytes indicated good stability at the storage temperature, 95.4–96.1% of the original concentration was found after storage period of 28 days.

Freeze and thaw stability. Freeze and thaw stability (Table 3) was consistent with previously reported data by Silva *et al.*¹² and Ilomuanya *et al.*¹⁵ for MET stability. Ilomuanya *et al.*¹⁵ in his freeze/thaw cycle evaluations indicated that after the fourth freeze/thaw cycle the concentrations of MET was $< 90\%$, suggesting that MET is not very stable after three freeze/thaw cycles. This is however the first reported ultra-filtrate stability data for CEF.

Short term stability or bench-top stability. Plasma samples at low and high quality control levels were kept at room temperature for a minimum of eight hours, then processed and analyzed (Table 3). Some studies have reported stabilities of metronidazole over a longer duration than in this method^{12,15}. Our choice for the 8 h period was to report an analytically relevant study under which the three drugs can be analyzed. The results indicated that the drugs were stable and therefore the sample processing procedure outlined within this method can be used to process large number of samples without the risk of sample degradation due to room temperature exposure.

Silva *et al.*¹² reported the stability of MET over a period of 48h, the mean stability ranging between 93.6% – 100.6%. This stability data was in agreement with what we have reported in this method, however we report the first stability study of MET-OH and CEF in plasma ultra-filtrate.

Table 3. Stability (ST%) of metronidazole (MET), ceftriaxone (CEF), hydroxymetronidazole (MET-OH) with the coefficient of variation (CV%) in plasma and CEF in ultra-filtrate (CEF^{uf}) (n=5).

| Stability parameters | Spiked conc. ($\mu\text{g/mL}$) | MET | | CEF | | MET-OH | | CEF ^{uf} | |
|--|------------------------------------|-------|-------|------|--------|--------|-------|-------------------|-------|
| | | 0.15 | 40 | 1.2 | 240 | 0.06 | 24 | 1.2 | 240 |
| Benchtop stability in matrix (room temperature, 8 h) | Mean of stability of samples | 0.16 | 39.32 | 1.18 | 230.4 | 0.059 | 24.52 | 1.19 | 253.9 |
| | CV % | 3.8 | 1.4 | 4.4 | 2.5 | 1.5 | 3.5 | 2.4 | 1.9 |
| | ST % | 105.8 | 98.3 | 98.1 | 96.0 | 99.5 | 102.2 | 99.8 | 105.8 |
| Freeze-thaw stability (3 freeze-thaw cycles at -20°C) | Mean of stability of samples | 0.14 | 37.40 | 1.15 | 228.6 | 0.058 | 24.18 | 1.12 | 221.3 |
| | CV % | 3.2 | 1.8 | 3.4 | 2.7 | 5.1 | 4.1 | 4.4 | 3.1 |
| | ST % | 96.1 | 93.5 | 95.8 | 95.3 | 97.2 | 100.7 | 93.0 | 92.2 |
| Auto-sampler stability (24 h at 18°C) | Mean of stability of samples | 0.15 | 37.50 | 1.09 | 228.9 | 0.062 | 22.27 | 1.18 | 226.1 |
| | CV % | 3.3 | 4.3 | 5.7 | 5.4 | 5.0 | 5.6 | 7.1 | 9.6 |
| | ST % | 101.5 | 93.7 | 90.6 | 95.4 | 103.3 | 92.8 | 98.4 | 94.2 |
| Long-term stability (90 days at -20°C) | Mean of stability of samples | 0.14 | 37.52 | 1.11 | 217.4 | 0.059 | 22.08 | 1.13 | 221.8 |
| | CV % | 6.0 | 4.7 | 4.2 | 7.3 | 1.4 | 5.6 | 3.1 | 5.6 |
| | ST % | 95.2 | 93.8 | 92.2 | 90.6 | 99.1 | 92.0 | 94.4 | 92.4 |
| Sub-stock solution stability (28 days at -20°C) | Nominal Conc. ($\mu\text{g/mL}$) | | 50 | | 300 | | 30 | | |
| | Mean of stability of samples | | 47.89 | | 288.39 | | 28.63 | | |
| | CV % | | 3.1 | | 2.8 | | 3.4 | | |
| | ST % | | 95.8 | | 96.1 | | 95.4 | | |

24 h stability in the autosampler. The results of post processing stability in Table 3 indicated that all the drugs were stable after 24 h in the autosampler and the integrity of data obtained after such re-assay would not be questionable. Ilomuanya *et al.*¹⁵ reported the autosampler stability of MET for 72h, however the data reported showed that MET was stable up to 24h and at 72h, the stability was greatly reduced to 40.6%–58.7%.

Long term stability at -20°C. The stability data reported in this study show that all the analytes were stable (90.6%–99.1%) within the period investigated. Since the stability at -20°C was acceptable, there was no need to evaluate the stability at -80°C, as our aim was to report a method that is affordable to resource limited laboratories.

Carry-over. No significant peak indicating carry-over was detected.

Matrix effect (ME%). The protein precipitation method of sample preparation is known to be prone to matrix effect^{36,37}. Chromatography of analytes or IS, as well as accuracy of the method may be affected by matrix effect, ion suppression or enhancement, due to co-eluting endogenous components. The matrix effect assessment Figure S2A (iv) revealed that only MET showed interference (ion enhancement) at its retention time. The matrix effect encountered with this method (Table S3) was much lower than in the previously reported method¹⁵, this could be attributed to the small sample volumes that were used in our sample processing.

$$ME\% = \frac{Response_{POEM}}{Response_{NEAT}} \times 100\%. \quad (iii)$$

Response_{POEM} is the average concentration of post extraction spiked matrix and Response_{NEAT} is the average concentration of the analyte in a neat solution.

The samples were prepared at two concentrations and the matrix effect determined as 107.6% (0.15 µg/mL) and 102.1% (40 µg/mL), *n*=6 at both levels. The values obtained at both levels were above 100% indicating the plasma-induced ion enhancement on the analysis of MET and suggesting that the endogenous compounds increased the signal intensity of the analyte in positive ESI mode. The effect of signal enhancement was higher at low concentration level.

Incurring sample reanalysis (ISR)

Incurring sample reanalysis conducted on 25 samples showed more than 67% had results within the accepted limits (< 20%) of variation. The mean variation of the analytes for the reanalysis were

5.7% (MET), 7.4% (MET-OH) and 7.0% (CEF), therefore, the reported subject sample analyte concentrations can be considered reliable and a true representation of the drug levels at the respective sampling times. Since sample storage was in plasma form, it was not necessary to perform reanalysis on the plasma ultra-filtrate.

Application of the method to real patient samples

The Optimising Antibiotic Treatment for Sick Malnourished Children (FLACSAM-PK) study was registered (NCT02746276) at ClinicalTrials.gov³⁸.

The validated method was successfully applied to a pharmacokinetic study of CEF, MET, MET-OH and unbound ceftriaxone in hospitalized children with complicated severe acute malnutrition (SAM) following an oral administration of MET and intravenous administration of CEF over the course of 72 hours.

81 hospitalized children with SAM and requiring IV antibiotics according to WHO and national guidelines were recruited (after obtaining ethical approval from the Kenya Medical Research Institute Scientific and Ethics Review Unit, approval number: KEMRI/SERU/CGMR-C023-3161 and informed consent from the parents/guardians) and treated with an oral dose of 7.5mg/Kg MET (Flagyl® oral suspension, 200 mg/5 mL) three times daily and IV injection of 80 mg/kg CEF (Ceftriaxone Rocephin®, 250 mg) once daily 15 min after metronidazole dose. Blood samples (3.0 mL) were collected into Li-heparinized tubes, a pre-dose sample was taken before administering the drugs. Further sampling at 5, 30, 60 min after ceftriaxone dose and 2, 4, and 8 h after metronidazole dose. The sampling plan was such that each patient had only three blood draws after the base-line sample. The blood was centrifuged (3000 rpm; 5 min), plasma separated and stored at -80°C until analysis time.

The patient samples were successfully analyzed using this method and no interference of endogenous compounds resulting from altered plasma protein compositions was encountered. Figure 3, shows a concentration–time profile of a baseline and three post-dose samples from a patient who had previously taken at least one metronidazole dose prior to study enrolment, this was evident from the significant levels of metronidazole and hydroxymetronidazole detected from the baseline sample.

We also addressed the recommendations by Wong *et al.*¹⁷, as this method allows for direct measurement of unbound ceftriaxone from only 25 µL plasma ultra-filtrate. Figure 4 shows representative chromatograms of processed plasma samples from one of the study participants.




Figure 3. Example concentration-time data of each of the four blood samples (baseline and 3 post first dose), where ceftriaxone, metronidazole and hydroxymetronidazole were quantified. In 2 samples, unbound ceftriaxone was also quantified. This example shows a patient who has clearly taken at least one previous dose of metronidazole prior to study enrolment.


A

Figure 4A. Representative chromatograms from processed plasma study sample at baseline before drug administration with undetectable levels of the drugs..


B

Figure 4B. Representative chromatograms of ceftriaxone 266.27 μ g/mL (RT 2.59 min), metronidazole 2.54 μ g/mL (RT 2.67 min), hydroxymetronidazole 0.13 μ g/mL (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from processed plasma study sample at 5 min after administering ceftriaxone IV.


C

Figure 4C. Representative chromatograms of ceftriaxone 74.39 μ g/mL (RT 2.59 min), metronidazole 1.99 μ g/mL (RT 2.67 min), hydroxymetronidazole 0.66 μ g/mL (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from processed plasma study sample at 30 min after administering ceftriaxone IV.

Conclusions

The validated HPLC–ESI–MS/MS method allowed the simultaneous quantitation of metronidazole, hydroxymetronidazole, ceftriaxone from only 50 µL human plasma, and of unbound ceftriaxone from 25 µL plasma ultra-filtrate. It provided simple and rapid analyses, as well as sensitive and reliable results. Thus, this method is suitable for routine high-throughput analyses and may be successfully applied to pharmacokinetic and bioequivalence of multiple doses evaluated in the present work in human subjects. The small sample volumes used makes it applicable to pediatric pharmacokinetics and bioequivalence studies, in which large sample volumes maybe unethical or impractical to obtain.

Competing interests

No competing interests were disclosed. No writing assistance was utilized in the production of this manuscript.

Grant information

JS has received funding from United Kingdom Medical Research Council Fellowships (grants G1002305 and M008665), and been supported by the National Institute for Health. KK has received funding from the People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme (FP7/2007-2013) under REA grant agreement no. 608765 and from the Estonian Research Council grant agreement PUTJD 22. JB received funding for this work within the First-Line Antimicrobials in Children with Complicated Severe Acute Malnutrition (FLACSAM) trial from the MRC/DfID/Wellcome Trust Joint Global Health Trials Scheme (MR/M007367/1), and is funded by the Bill & Melinda Gates Foundation for the Childhood Acute Illness & Nutrition (CHAIN) Network (OPP1131320).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Supplementary materials

Figure S1. MRM product ion spectra of protonated (i) CEF (m/z 555.1→ m/z 396.0), (ii) MET (m/z 172.2→ m/z 128.2), (iii) MET-OH (m/z 188.0→ m/z 125.9) and ammonium adduct of (iv) CEFU (m/z 528.1→ m/z 364.0).

[Click here to access the data.](#)

Figure S2. Representative chromatograms of a direct post column infusion of blank extracted plasma (A, i-iv), MET at ULOQ (A, v) and a blank extracted neat solution showing absence of matrix effect (B, i-iv).

[Click here to access the data.](#)

Table S1. Regression parameters for ceftriaxone (CEF), metronidazole (MET) and hydroxymetronidazole (MET-OH) in spiked plasma.

[Click here to access the data.](#)

Table S2. Extraction recoveries of ceftriaxone (CEF), metronidazole (MET), hydroxymetronidazole (MET-OH) and cefuroxime (CEFU) from spiked plasma samples and in ultra-filtrate. Standard deviation (SD); coefficient of variation (CV); internal standard (IS); n=6.

[Click here to access the data.](#)

Table S3. Matrix effects (ME %) for metronidazole (MET) in 6 plasmas. Standard deviation (SD); coefficient of variation (CV); internal standard (IS); n=6.

[Click here to access the data.](#)

References

- Maitland K, Berkley JA, Shebbe M, *et al.*: **Children with Severe Malnutrition: can Those at Highest Risk of Death Be Identified with the WHO Protocol?** *PLoS Med.* 2006; 3(12): e500.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Vincent JL, Rello J, Marshall J, *et al.*: **International study of the prevalence and outcomes of infection in intensive care units.** *JAMA.* 2009; 302(21): 2323–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Tickell KD, Denno DM: **Inpatient management of children with severe acute malnutrition: a review of WHO guidelines.** *Bull World Health Organ.* 2016; 94(9): 642–51.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Berkley JA, Ngari M, Thitiri J, *et al.*: **Daily co-trimoxazole prophylaxis to prevent mortality in children with complicated severe acute malnutrition: a multicentre, double-blind, randomised placebo-controlled trial.** *Lancet Glob Health.* 2016; 4(7): 464–73.
[PubMed Abstract](#) | [Publisher Full Text](#)

5. Kollef MH, Sherman G, Ward S, *et al.*: Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. *Chest*. 1999; 115(2): 462–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Garnacho-Montero J, Garcia-Garmendia J, Barrero-Almodovar A, *et al.*: Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. *Crit Care Med*. 2003; 31(12): 2742–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Harbarth S, Garbino J, Pugin J, *et al.*: Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. *Am J Med*. 2003; 115(7): 529–35.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Lazzerini M, Tickell D: Antibiotics in severely malnourished children: systematic review of efficacy, safety and pharmacokinetics. *Bull World Health Organ*. 2011; 89(8): 594–607.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Williams P, Berkley J: Severe acute malnutrition update: current WHO guidelines and the WHO essential medicine list for children. 2016.
[Reference Source](#)
10. Easmon CS, Ison CA, Kaye CM, *et al.*: Pharmacokinetics of metronidazole and its principal metabolites and their activity against *Gardnerella vaginalis*. *Br J Vener Dis*. 1982; 58(4): 246–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. O'Keefe JP, Troc KA, Thompson KD: Activity of metronidazole and its hydroxy and acid metabolites against clinical isolates of anaerobic bacteria. *Antimicrob Agents Chemother*. 1982; 22(3): 426–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Silva M, Schramm S, Kano E, *et al.*: Development and validation of a HPLC-MS-MS method for quantification of metronidazole in human plasma. *J Chromatogr Sci*. 2009; 47(9): 781–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Ezzeldin E, El-Nahhas T: New Analytical Method for the Determination of Metronidazole in Human Plasma: Application to Bioequivalence Study. *Tropical Journal of Pharmaceutical Research*. 2012; 11(5): 799–805.
[Publisher Full Text](#)
14. Kurji HA, Ghareeb MM, Zalzal MH, *et al.*: Serum Level Profile and Pharmacokinetic Parameters of Single Oral Dose of Metronidazole in Type II Diabetic Patients. *Iraqi J Pharm Sci*. 2011; 20(1): 14–8.
[Reference Source](#)
15. Ilomuanya M, Uboh C, Ciallella J, *et al.*: Analysis of metronidazole in equine plasma using liquid chromatography/tandem mass spectrometry and high-resolution accurate mass spectrometry. *Rapid Commun Mass Spectrom*. 2015; 29(8): 753–63.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Houghton GW, Hundt HK, Muller FO, *et al.*: A comparison of the pharmacokinetics of metronidazole in man after oral administration of single doses of benzoylmetronidazole and metronidazole. *Br J Clin Pharmacol*. 1982; 14(2): 201–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Wong G, Briscoe S, Adnan S, *et al.*: Protein binding of β -lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? *Antimicrob Agents Chemother*. 2013; 57(12): 6165–70.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Schleibinger M, Steinbach CL, Töpper C, *et al.*: Protein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patients. *Br J Clin Pharmacol*. 2015; 80(3): 525–33.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Heuberger J, Schmidt S, Derendorf H: When is protein binding important? *J Pharm Sci*. 2013; 102(9): 3458–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. De Cock RD, Smits A, Allegaert K, *et al.*: Population pharmacokinetic modelling of total and unbound cefazolin plasma concentrations as a guide for dosing in preterm and term neonates. *J Antimicrob Chemother*. 2014; 69(5): 1330–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Blot SI, Pea F, Lipman J: The effect of pathophysiology on pharmacokinetics in the critically ill patient—concepts appraised by the example of antimicrobial agents. *Adv Drug Deliv Rev*. 2014; 77: 3–11.
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Berezhkovskiy LM: On the temperature dependence of the unbound drug fraction in plasma: Ultrafiltration method may considerably underestimate the true value for highly bound drugs. *Drug Discov Ther*. 2008; 2(2): 74–6.
[PubMed Abstract](#)
23. Joynt GM, Lipman J, Gomersall CD, *et al.*: The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. *J Antimicrob Chemother*. 2001; 47(4): 421–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Zhang J, Musson DG: Investigation of high-throughput ultrafiltration for the determination of an unbound compound in human plasma using liquid chromatography and tandem mass spectrometry with electrospray ionization. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2006; 843(1): 47–56.
[PubMed Abstract](#) | [Publisher Full Text](#)
25. van Liempd S, Morrison D, Sysmans L, *et al.*: Development and validation of a higher-throughput equilibrium dialysis assay for plasma protein binding. *J Lab Autom*. 2011; 16(1): 56–67.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Sultana N, Arayne M, Shahzad W: Simultaneous Determination of Ceftriaxone Sodium and Non Steroidal Anti-Inflammatory Drugs in Pharmaceutical Formulations and Human Serum by RP-HPLC. *J Chin Chem Soc-Taipei*. 2010; 57(6): 1278–85.
[Publisher Full Text](#)
27. Sun H, Wang H, Ge X, *et al.*: Simultaneous Determination of the combined drugs Ribavirin and Ceftriaxone sodium in human urine by HPLC-DAD. *Int Journal of Sc Innovations and Disc*. 2011; 1(2): 216–25.
28. Sun H, Wang H, Ge X: Simultaneous determination of the combined drugs of ceftriaxone sodium, metronidazole, and levofloxacin in human urine by high-performance liquid chromatography. *J Clin Lab Anal*. 2012; 26(6): 486–92.
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Sar T, Mandal T, Das S, *et al.*: Pharmacokinetics of Ceftriaxone in Healthy and Mastitic Goats With Special Reference to Its Interaction. With Polyherbal Drug (Fibrosin®). *Intern J Appl Res Vet Med*. 2006; 4(2): 142–54.
[Reference Source](#)
30. Administration UDOHaHSFaD: Guidance for Industry: Bioanalytical method validation. 2013.
[Reference Source](#)
31. European Medicines Agency: Guideline on Validation of Bioanalytical Methods. 2011.
[Reference Source](#)
32. Deshpand A, Baheti K, Chatterjee N: Degradation of Beta-lactam antibiotics. *Current Science*. 2004; 87(12): 1684–95.
[Reference Source](#)
33. Frau J, Coll M, Donoso J, *et al.*: Alkaline and acidic hydrolysis of the beta-lactam ring. *Electron J Theor Chem*. 1997; 2: 56–65.
[Publisher Full Text](#)
34. Beale J Jr, Block J: Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry. 12th ed: Lippincott Williams & Wilkins; 1998.
[Reference Source](#)
35. Lemke T, Williams D: Foye's Principles of Medicinal Chemistry. 6th ed. 2008.
[Reference Source](#)
36. Kruve A, Rebane R, Kipper K, *et al.*: Tutorial review on validation of liquid chromatography-mass spectrometry methods: part I. *Anal Chim Acta*. 2015; 870: 29–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Kruve A, Rebane R, Kipper K, *et al.*: Tutorial review on validation of liquid chromatography-mass spectrometry methods: part II. *Anal Chim Acta*. 2015; 870: 8–28.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Optimising Antibiotic Treatment for Sick Malnourished Children (FLACSAM-PK). 2016.
[Reference Source](#)

Open Peer Review

Current Referee Status:



Version 2

Referee Report 21 February 2018

doi:[10.21956/wellcomeopenres.14807.r30386](https://doi.org/10.21956/wellcomeopenres.14807.r30386)



Sandrine Lefeuve

Laboratory of Biochemistry, CHR Orléans, Orléans, France

In the "Preparation of analytical standards", QC levels (LLOQ) are missing.

The exception of that, I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 06 February 2018

doi:[10.21956/wellcomeopenres.14807.r30385](https://doi.org/10.21956/wellcomeopenres.14807.r30385)



I-Lin Tsai

Department of Biochemistry and Molecular Cell Biology, Taipei Medical University, Taipei, Taiwan

The revised manuscript can be accepted to be indexed.

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Referee Report 02 February 2018

doi:[10.21956/wellcomeopenres.14807.r30387](https://doi.org/10.21956/wellcomeopenres.14807.r30387)



Pascal Houzé

CNRS (French National Center for Scientific Research) UMR8258 - U1022, Faculty of Pharmacy, Paris Descartes University, Paris, France

In view of the authors' replies to the questions asked in my first report and in view of the changes made to the text and figures to answer these questions, I give a favorable opinion to the publication of this article.

Competing Interests: No competing interests were disclosed.

Referee Expertise: Analytical Chemistry, Toxicology

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Referee Report 17 November 2017

doi:[10.21956/wellcomeopenres.12670.r26950](https://doi.org/10.21956/wellcomeopenres.12670.r26950)



Pascal Houzé

CNRS (French National Center for Scientific Research) UMR8258 - U1022, Faculty of Pharmacy, Paris Descartes University, Paris, France

The authors report the development of the determination of ceftriazone and metronidazole in children by liquid chromatography coupled with mass spectrometry. Therapeutic adaptation in children is particularly important and especially in malnourished children. The theme developed by the authors is therefore totally up to date.

In general, the article is well constructed and the validation of method correctly performed in part on the study of stability performed under very varied conditions.

However, different points need to be clarified:

The introduction:

- Why did the authors not also measure the acid metabolite of metronidazole which is active as the parent molecule and the alcohol metabolite? To be explained by the authors

The material and methods

- Why the authors dilute the eluent to 1/5 in an aqueous solution of 20% methanol. Why such a large dilution? Why use an aqueous solution of methanol to dilute and not use mobile phase A?
- Would it not have been better to evaporate acetonitrile and take up the dry residue with mobile phase?
- For the quantification of the unbound fraction why do the authors start with 300 µl of serum to finally dilute in 1 ml of aqueous solution of methanol. Why not use less plasma and not dilute in such a large volume?
- The 300 µL used are a little high to qualify the method of micromethode as done by the authors

- For the quantification of the unbound fraction, what is the interest of incubating the plasma for 1 hour at 37 ° C before proceeding to ultrafiltration? Authors should explain this step
- the linearity domains for each molecule must be indicated in the paragraph corresponding to the preparation of the analytical standards
- how are the controls prepared for the study of the precision and accuracy of the method

The results and discussion

- In the section selectivity I do not understand the legend of Figure 2. In the text the authors speak of 4 chromatograms: Extracted blank, blank plasma spiked with IS, a spiked plasma with the analytes at LLOQ and ULOQ. Figure 2 shows only 3 chromatograms (A, B and C) and to my avsi, the legends indicated do not correspond to the chromatograms presented. This point is major and must be clarified by the authors
- How did the authors determine the ULOQ values for all the measured compounds?
- For me the authors chose a bad example to illustrate their method of dosage. They should choose another child for whom there is no metronidazole at time T0. On the other hand, the chromatograms presented in FIG. 4 should correspond to those of the kinetics presented. Indeed, in FIG. 4A, chromatogram before injection, there is no peak of metronidazole nor of its metabolite, so this does not correspond to the chromatograms of the kinetics of FIG. 3
- Why was the determination of the unbound fraction of ceftriazone made only at 2 times and the determination of the total?
- How can the authors explain a very high concentration of free ceftriazone at T0 while the total form is undetectable at the same time? form at 4 times?

In conclusion, subject to making the changes mentioned above and especially to review the clinical illustration part of the end of article, this manuscript could be accepted for indexing.

Is the rationale for developing the new method (or application) clearly explained?

Yes

Is the description of the method technically sound?

Partly

Are sufficient details provided to allow replication of the method development and its use by others?

Yes

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?

Partly

Competing Interests: No competing interests were disclosed.

Referee Expertise: Analytical Chemistry, Toxicology

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 10 Dec 2017

Karin Kipper, St George's, University of London, UK

Responses to the comments by Pascal Houzé.

The authors report the development of the determination of ceftriazone and metronidazole in children by liquid chromatography coupled with mass spectrometry. Therapeutic adaptation in children is particularly important and especially in malnourished children. The theme developed by the authors is therefore totally up to date.

In general, the article is well constructed and the validation of method correctly performed in part on the study of stability performed under very varied conditions.

However, different points need to be clarified:

The introduction:

- Why did the authors not also measure the acid metabolite of metronidazole which is active as the parent molecule and the alcohol metabolite? To be explained by the authors

Response: Respectfully, it is true that both metabolites are pharmacologically active. The major active metabolite however is the alcohol metabolite, we therefore measured the metabolite that would cause a significant clinical effect on the patient. (Manuscript changed to explain this).

The material and methods

- Why the authors dilute the eluent to 1/5 in an aqueous solution of 20% methanol. Why such a large dilution? Why use an aqueous solution of methanol to dilute and not use mobile phase A?

Response:

This study involved analysis of samples from multiple dosing with the study drug, high concentrations thus necessitated the large dilutions to levels optimal for MS detection. The method aimed at quantifying multiple drugs with varied physicochemical properties simultaneously. Whereas use of mobile phase A looks conventional, it was tried and found unsuitable due to poor chromatographic peak shapes.

Would it not have been better to evaporate acetonitrile and take up the dry residue with mobile phase?

Response:

Respectfully, whereas evaporating acetonitrile and reconstituting the residue could have resulted into better sample purification, we were not keen to adopt that method since we found it much laborious and time consuming. Furthermore the drug levels we anticipated were high enough and pre-concentration was not our priority.

For the quantification of the unbound fraction why do the authors start with 300 µl of serum to finally dilute in 1 ml of aqueous solution of methanol? Why not use less plasma and not dilute in such a large volume?

Response:

The ultrafiltration device used to obtain the ultrafiltrate by filtration retain plasma proteins and only the ultrafiltrate to pass through. If smaller volumes of plasma were used, not sufficient ultrafiltrate would be obtained with the recommended maximum speed of x 2000g.

The 300 µL used are a little high to qualify the method of micromethode as done by the authors

Response: The qualification is relative to the previous work done in other publications where sample volumes as high as 500mL were used to determine free fractions using a similar technique of ultrafiltration.

For the quantification of the unbound fraction, what is the interest of incubating the plasma for 1 hour at 37 ° C before proceeding to ultrafiltration? Authors should explain this step

Response:

Kindly, this is well explained in the 1st paragraph of results and discussion.

The equilibrium between the bound and free fractions of ceftriaxone is temperature dependant, maintaining a physiological temperature through the process is key for a more realistic representation of unbound fractions of the drug.

the linearity domains for each molecule must be indicated in the paragraph corresponding to the preparation of the analytical standards

Response:

Manuscript changed to include the linearity domains for each molecule under preparation of analytical standards.

how are the controls prepared for the study of the precision and accuracy of the method

Response: Manuscript changed to include the information.

The results and discussion

In the section selectivity I do not understand the legend of Figure 2. In the text the authors speak of 4 chromatograms: Extracted blank, blank plasma spiked with IS, a spiked plasma with the analytes at LLOQ and ULOQ. Figure 2 shows only 3 chromatograms (A, B and C) and to my avsi, the legends indicated do not correspond to the chromatograms presented. This point is major and must be clarified by the authors

Response:

This was a mislabeled figure legend.

- **Figure 2A: Representative chromatograms from extracted zero sample (with IS only), cefuroxime (RT 3.71 min) .Changes made to manuscript.**

- **Figure 2B: Representative chromatograms of ceftriaxone (RT 2.59 min), metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from extracted spiked plasma at LLOQ .Changes made to manuscript.**
- **Figure 2C: Representative chromatograms of ceftriaxone (RT 2.59 min), metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from extracted spiked plasma at ULOQ. Changes made to manuscript.**

How did the authors determine the ULOQ values for all the measured compounds?

Response:

- **The ULOQ values were determined from anticipated peak concentrations ranges of the analytes, and ensuring that the calibration points met the accuracy and reproducibility criteria of method validation. (Manuscript changed to include this in the calibration curves and limits of quantification section).**

For me the authors chose a bad example to illustrate their method of dosage. They should choose another child for whom there is no metronidazole at time T0. On the other hand, the chromatograms presented in FIG. 4 should correspond to those of the kinetics presented. Indeed, in FIG. 4A, chromatogram before injection, there is no peak of metronidazole nor of its metabolite, so this does not correspond to the chromatograms of the kinetics of FIG. 3

Response:

Manuscript changed for Fig.4 to correspond to the concentration-time data of kinetics in Fig.3

Why was the determination of the unbound fraction of ceftriazone made only at 2 times and the determination of the total?

Response:

Unbound ceftriaxone was measured at only 2 time points, the first time point was drawn 5 min after ceftriaxone iv administration (peak). The second time point was taken at the trough (90 min) after drug administration. Protein binding of ceftriaxone is inversely proportional to plasma concentrations, determining unbound ceftriaxone at the two time points still gave sufficient data to characterize protein binding of the drug.

How can the authors explain a very high concentration of free ceftriazone at T0 while the total form is undetectable at the same time? form at 4 times?

Response:

Free ceftriaxone was measured at only 2 time points, the first time point was drawn 5 min after ceftriaxone iv administration (not T0). The second time point was taken at the trough (90 min) after drug administration. Baseline sample was not analyzed for free ceftriaxone since no drug was anticipated at this point.

The first time point for total ceftriaxone is a baseline sample and thus undetectable level is expected. The 1st time point for total ceftriaxone therefore corresponds to the 2nd time point for unbound ceftriaxone. (Manuscript edited to clarify this)

In conclusion, subject to making the changes mentioned above and especially to review the clinical

illustration part of the end of article, this manuscript could be accepted for indexing.

Response: Thank you.

Competing Interests: No competing interests were disclosed.

Referee Report 16 November 2017

doi:[10.21956/wellcomeopenres.12670.r26951](https://doi.org/10.21956/wellcomeopenres.12670.r26951)



Sandrine Lefeuve

Laboratory of Biochemistry, CHR Orléans, Orléans, France

- Calibration and QCs preparation was not clearly explained. A paragraph detailing the preparation of calibrators and QCs in plasma and those used for unbound fraction is missing. How many points? Which matrix is used to quantify the free fraction?
- Target antibiotic concentrations should be determined for each patient, depending on the strain and the MIC. Has the MIC been taken into account to build the calibration range?
- Did the authors consider the impact of adding more methanol in preparing the high QC compared to the low QC? Furthermore, I am concerned that the different sample types (i.e. calibrators, QCs, and patient samples) were handled distinctly, especially with respect to the amount of methanol added to the sample prior to extraction.
- Why 6 min for the re-equilibration step of the analytical column? Could you explain?
- Dilution integrity was not experimented to validate the dilution test to be carried out on drug concentration beyond the calibration interval. Considering the wide range of concentrations expected at different stages of a treatment, the dilution process must be validated according to EMA guidelines
- Incurred sample reanalysis is missing. Differences for instance in protein binding, sample inhomogeneity or concomitant medications, may affect the accuracy and precision of the analyte in such samples during processing and storage. It is therefore recommended to evaluate accuracy of incurred samples by reanalysis of study samples. In accordance with FDA and EMA guidelines.
- The 3 paragraphs (below) p9 should be in the Materials and Methods section. Not in the Results section

p9: "Accuracy and precision. To evaluate the inter-assay precision and accuracy, six replicates of quality control plasma samples were analyzed together with one independent calibration A similar assessment was done for plasma ultra-filtrate to determine the accuracy and precision for the unbound ceftriaxone."

p9: Carry-over. "A processed blank sample was injected after a high concentration calibration standard at the upper limit of quantification (ULOQ)."

p9 Matrix effect (ME%). "Two different methods were used to access and determine matrix effect. In the first method, regions of ion suppression or enhancement were evaluated by direct post column infusion of a mixture of analytes and IS at high concentration at the rate of 10 $\mu\text{L}/\text{min}$, while injecting a blank extracted plasma." ... And "In the second method, matrix effect (ion enhancement) was evaluated for MET in six different lots of plasma by comparing the response of post extracted plasma samples spiked with 0.15 $\mu\text{g}/\text{mL}$ (LLOQ) and 40 $\mu\text{g}/\text{mL}$ (ULOQ) of metronidazole with the response of neat standard solutions spiked at similar concentrations."

- CEF is highly bound to proteins ; average protein binding of 89.5%. Could you explain Figure 3? Protein binding seem strongly affected.

Is the rationale for developing the new method (or application) clearly explained?

Yes

Is the description of the method technically sound?

Partly

Are sufficient details provided to allow replication of the method development and its use by others?

Partly

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?

Yes

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 10 Dec 2017

Karin Kipper, St George's, University of London, UK

Responses to the comments by Sandrine Lefeuve.

Calibration and QCs preparation was not clearly explained. A paragraph detailing the preparation of calibrators and QCs in plasma and those used for unbound fraction is missing. How many points? Which matrix is used to quantify the free fraction?

Response:

The manuscript edited to include a detailed preparation of calibrators and QC samples in plasma as well as in measurement of unbound fraction. Text added to the manuscript: The matrix used to quantify free fraction of ceftriaxone was plasma ultrafiltrate obtained by ultrafiltration of drug-free plasma.

Target antibiotic concentrations should be determined for each patient, depending on the strain and the MIC. Has the MIC been taken into account to build the calibration range?

Response:

Yes, this was considered. An extensive discussion of the same is contained in a separate publication on “Dosing of ceftriaxone and metronidazole in infants with severe acute malnutrition”.

Did the authors consider the impact of adding more methanol in preparing the high QC compared to the low QC? Furthermore, I am concerned that the different sample types (i.e. calibrators, QCs, and patient samples) were handled distinctly, especially with respect to the amount of methanol added to the sample prior to extraction.

Response: This was considered. Whereas 400µl of 20% methanol was used in both QCs and patient samples during processing, the calibrators and QCs were pre-spiked with only 25 µl (for 425 µl drug-free plasma).

Why 6 min for the re-equilibration step of the analytical column? Could you explain?

Response: The gradient elution used resulted in variation in column pressure with change in mobile phase proportions. The 6 min was to allow column pressure to equilibrate to avoid shifting of peaks.

Dilution integrity was not experimented to validate the dilution test to be carried out on drug concentration beyond the calibration interval. Considering the wide range of concentrations expected at different stages of a treatment, the dilution process must be validated according to EMA guidelines

Response: None of the study samples were above upper limit of quantification nor needed dilution. Dilution integrity was not assessed for this method.

Incurred sample reanalysis is missing. Differences for instance in protein binding, sample inhomogeneity or concomitant medications, may affect the accuracy and precision of the analyte in such samples during processing and storage. It is therefore recommended to evaluate accuracy of incurred samples by reanalysis of study samples. In accordance with FDA and EMA guidelines.

Response: Incurred sample reanalysis was done for study samples and mean variation (accuracy of the re-analysis) for all the analytes was 5.7%-7.4%. Information was added to the manuscript.

The 3 paragraphs (below) p9 should be in the Materials and Methods section. Not in the Results section

p9: “Accuracy and precision. To evaluate the inter-assay precision and accuracy, six replicates of

quality control plasma samples were analyzed together with one independent calibration A similar assessment was done for plasma ultra-filtrate to determine the accuracy and precision for the unbound ceftriaxone.”

p9: Carry-over. “A processed blank sample was injected after a high concentration calibration standard at the upper limit of quantification (ULOQ).”

p9 Matrix effect (ME%).”Two different methods were used to access and determine matrix effect. In the first method, regions of ion suppression or enhancement were evaluated by direct post column infusion of a mixture of analytes and IS at high concentration at the rate of 10 $\mu\text{L}/\text{min}$, while injecting a blank extracted plasma.” ... And“ In the second method, matrix effect (ion enhancement) was evaluated for MET in six different lots of plasma by comparing the response of post extracted plasma samples spiked with 0.15 $\mu\text{g}/\text{mL}$ (LLOQ) and 40 $\mu\text{g}/\text{mL}$ (ULOQ) of metronidazole with the response of neat standard solutions spiked at similar concentrations.”

Response: Thank you. The manuscript edited to include procedures of accuracy and precision, carry-over and matrix-effect in the methods section.

CEF is highly bound to proteins; average protein binding of 89.5%. Could you explain Figure 3? Protein binding seem strongly affected.

Response: Respectfully, whereas CEF is known to be highly protein bound, inter patient variability is expected in this category of patients due to their age band and also the prevalence of hypoalbuminemia resulting into altered protein binding. We have explained this in a separate publication.

Competing Interests: No competing interests were disclosed.

Referee Report 24 October 2017

doi:[10.21956/wellcomeopenres.12670.r26783](https://doi.org/10.21956/wellcomeopenres.12670.r26783)



I-Lin Tsai

Department of Biochemistry and Molecular Cell Biology, Taipei Medical University, Taipei, Taiwan

In the manuscript entitled “Liquid chromatography–tandem mass spectrometry for the simultaneous quantitation of ceftriaxone, metronidazole and hydroxymetronidazole in plasma from seriously ill, severely malnourished children”, the authors developed and validated a LC-MS/MS method to quantify drugs from plasma. The following are some comments for the manuscript:

1. Are the chromatograms in 2A and 2B generated from blank samples spiked with drugs at LLOQ and ULOQ respectively? Please indicate the peaks in 2A. What are “zero sample LLOQ” and “zero sample ULOQ” in the figure legend? What are the criteria of LLOQ for each analyte? How the authors defined the LLOQ?
2. Please indicate the spiked concentrations in figure 2C?

3. Please indicate the quantified concentrations in Figure 4.

4. Please use true scale (intensity) instead of 100 % for all the figures.

Is the rationale for developing the new method (or application) clearly explained?

Yes

Is the description of the method technically sound?

Partly

Are sufficient details provided to allow replication of the method development and its use by others?

Yes

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?

Partly

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 10 Dec 2017

Karin Kipper, St George's, University of London, UK

Responses to the comments by I-Lin Tsai.

1. Are the chromatograms in 2A and 2B generated from blank samples spiked with drugs at LLOQ and ULOQ respectively? Please indicate the peaks in 2A. What are “zero sample LLOQ” and “zero sample ULOQ” in the figure legend? What are the criteria of LLOQ for each analyte? How the authors defined the LLOQ?

Response: This was a mislabelled figure legend.

- **Figure 2A:** Representative chromatograms from extracted zero sample (with IS only), cefuroxime (RT 3.71 min) .Changes made to manuscript.
- **Figure 2B:** Representative chromatograms of ceftriaxone (RT 2.59 min), metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from extracted spiked plasma at LLOQ .Changes made to manuscript.
- **Figure 2C:** Representative chromatograms of ceftriaxone (RT 2.59 min), metronidazole (RT 2.67 min), hydroxymetronidazole (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from extracted spiked plasma at ULOQ. Changes made to manuscript.

- The LLOQ is defined under the sub-heading “Calibration curves and limits of quantification” as the lowest standard on the calibration curve that the method is able to identify and quantify discretely with a precision $\leq 20\%$ and with an accuracy within 80%-120%. No change made to manuscript.

2. Please indicate the spiked concentrations in figure 2C?

Response: The response in 1 above regarding Fig 2C addresses this.

3. Please indicate the quantified concentrations in Figure 4.

Response: Manuscript edited with additional information to include concentrations at the sampling points as:

- Figure 4A: Representative chromatograms from processed plasma study sample at baseline before drug administration with undetectable levels of the drugs.
- Figure 4B: Representative chromatograms of ceftriaxone 266.27 $\mu\text{g/mL}$ (RT 2.59 min), metronidazole 2.54 $\mu\text{g/mL}$ (RT 2.67 min), hydroxymetronidazole 0.13 $\mu\text{g/mL}$ (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from processed plasma study sample at 5 min after administering ceftriaxone iv.
- Figure 4C: Representative chromatograms of ceftriaxone 74.39 $\mu\text{g/mL}$ (RT 2.59 min), metronidazole 1.99 $\mu\text{g/mL}$ (RT 2.67 min), hydroxymetronidazole 0.66 $\mu\text{g/mL}$ (RT 2.69 min) and cefuroxime (IS) (RT 3.71 min) from processed plasma study sample at 30 min after administering ceftriaxone iv.

4. Please use true scale (intensity) instead of 100 % for all the figures.

Response: Figures have been changed as requested.

Competing Interests: No competing interests were disclosed.

Referee Report 24 July 2017

doi:[10.21956/wellcomeopenres.12670.r24432](https://doi.org/10.21956/wellcomeopenres.12670.r24432)



Laurens Manning

Department of Infectious Diseases, Fiona Stanley Hospital, Murdoch, WA, Australia

This is a straightforward methods paper for a simultaneous LCMS assay for ceftriaxone + metronidazole (+metabolite) from malnourished children. The necessity for good quality drug assays for use in vulnerable populations is a critical component for optimized PK, PK/PD and efficacy studies in the future. However, whilst I agree with the need for such an assay, I have a few concerns about how the data are reported and some of the analytical processes.

1. The assay is being reported in the conclusion as a low volume assay, but 300 μL is required for the ultrafiltration component; I am not sure this can really be considered to be a microsampling technique. The total blood volume taken from very young, anaemic, malnourished children should be a consideration in assay development, and it will almost certainly be an issue for ethics review boards.

2. Stability of the plasma assay has been reported. One of the challenges of working in tropical countries is ensuring that the assay is fit for purpose with respect to sample handling in the field. Often there are delays to plasma separation and the samples may have other delays before being placed into freezer conditions. Our group believes that in tropical and resource poor settings, the assay should account for stability at room temp (not just benchtop stability), tropical ambient temperatures and at 4 degrees.
3. As this assay has been reported as a simultaneous assay, it would be good to see the chromatograms overlaid with the 3 analytes and IS.
4. Could the authors please clarify throughout the manuscript whether MRM or SRM has been used?
5. My major critique is that of the example child used for the validation paper; the authors describe how the assay was used successfully for 81 children; but present a time concentration curve from a single child. The T0 samples in this child had >40000ng/mL. The explanation given is that the child must have had prior exposure to metronidazole. Whilst this is likely to be true, I don't believe this is appropriate for a methods paper that describes the utility of the assay. I would recommend reporting another 'sample child' with a clear undetectable result at T0.

Is the rationale for developing the new method (or application) clearly explained?

Yes

Is the description of the method technically sound?

Partly

Are sufficient details provided to allow replication of the method development and its use by others?

Partly

If any results are presented, are all the source data underlying the results available to ensure full reproducibility?

Partly

Are the conclusions about the method and its performance adequately supported by the findings presented in the article?

Partly

Competing Interests: No competing interests were disclosed.

I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 18 Aug 2017

Karin Kipper, St George's, University of London, UK

Responses to the comments by Laurens Manning.

1. The assay is being reported in the conclusion as a low volume assay, but 300µL is required for the ultrafiltration component; I am not sure this can really be considered to be a microsampling technique. The total blood volume taken from very young, anaemic, malnourished children should be a consideration in assay development, and it will almost certainly be an issue for ethics review boards.

Response: This is a common misconception. For example, a 1ml sample taken at baseline then 3 time points for an 8kg child represents 0.6% of blood volume (80ml/kg) and would not have a measurable impact on haemoglobin concentration. No change to the manuscript.

2. Stability of the plasma assay has been reported. One of the challenges of working in tropical countries is ensuring that the assay is fit for purpose with respect to sample handling in the field. Often there are delays to plasma separation and the samples may have other delays before being placed into freezer conditions. Our group believes that in tropical and resource poor settings, the assay should account for stability at room temp (not just benchtop stability), tropical ambient temperatures and at 4 degrees.

Response: I don't think anyone should be doing PK studies if they cannot do the separation soon after the blood was drawn. Our samples were immediately taken to labs with AC in Kilifi & Mombasa and Nairobi. We can confirm that is room temperature remained <28 degrees in all sites, therefore additional stability experiments are not needed to cover the sampling time and temperatures. Comment will be added to the manuscript.

3. As this assay has been reported as a simultaneous assay, it would be good to see the chromatograms overlaid with the 3 analytes and IS.

Response: Respectfully, we thought the chromatograms are best as represented for ease of understanding and interpretation by the reader. Overlaid chromatograms would be necessary with UV detection where overlapping peaks could be troublesome in integration, fortunately that is not the case with MS. No change to manuscript.

4. Could the authors please clarify throughout the manuscript whether MRM or SRM has been used?

Response: MRM was employed as depicted from mass transitions in Table 1 and Figures 2 and 4. SRM was investigated during the early stages of compound optimization. The manuscript will be edited to clarify.

5. My major critique is that of the example child used for the validation paper; the authors describe how the assay was used successfully for 81 children; but present a time concentration curve from a single child. The T0 samples in this child had >40000ng/mL. The explanation given is that the child must have had prior exposure to metronidazole. Whilst this is likely to be true, I don't believe this is appropriate for a methods paper that describes the utility of the assay. I would recommend reporting another 'sample child' with a clear undetectable result at T0.

Response: Respectfully, we acknowledge this as a recommendation rather than a critique

since the request is to have additional 'sample child' with a clear undetectable result at T0 for comparability purposes and ease of interpretation. Full results of this study are being published separately.

Competing Interests: No competing interests were disclosed.
